EQS-News: Quantumzyme Announces Vision to Lead the Future of Sustainable Industrial Biocatalysis
Werte in diesem Artikel
EQS-News: Quantumzyme Corp
/ Key word(s): Manufacturing
Werbung Werbung SAN DIEGO, CA - March 27, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC:QTZM), a pioneering biotechnology company specializing in computational enzyme engineering, is proud to introduce its mission and vision to reshape global industries through precision biocatalysis. Quantumzyme specializes in developing custom-engineered enzymes that replace traditional chemical catalysts with clean, efficient, and scalable biological alternatives. By leveraging advanced molecular modeling, quantum chemistry, and artificial intelligence, the company is poised to create high-performance enzymes that it believes will be able to solve critical challenges across various industries pharmaceuticals, agriculture, energy, and specialty chemicals. Werbung Werbung Our Mission: To unlock the full potential of nature’s catalysts through cutting-edge science, enabling industries to produce more sustainably, more efficiently, and with greater precision. What Quantumzyme Does: Quantumzyme is engaged in engineering novel enzymes that enable chemical transformations with higher selectivity, lower energy consumption, and significantly reduced environmental impact. These biocatalysts are designed using a proprietary platform that integrates computational biology, machine learning, and molecular simulation - intended to dramatically accelerate the discovery-to-deployment timeline. Werbung Werbung Quantumzyme’s goal is for its technology to enable a new paradigm of clean manufacturing at scale. Vision and Goals:
Path to Market: Quantumzyme plans to commercialize its enzyme technology through strategic partnerships, licensing agreements, and co-development initiatives with leading companies in pharmaceuticals, specialty chemicals, and clean energy. The company also plans to develop pilot programs with manufacturers to validate and integrate its enzyme solutions into real-world production environments. The company’s business model combines deep tech R&D with scalable licensing, allowing for rapid adoption across industries while maintaining a lean, innovation-focused operation. “We believe enzymes are the future of clean industry,” stated Naveen Kulkarni, CEO of Quantumzyme Corp. “Our work is about enabling that future - faster, smarter, and more sustainably. Whether it’s making a drug safer to produce or turning waste into value, we’re here to catalyze that transformation.” With a vision rooted in science and a roadmap grounded in collaboration and scale, Quantumzyme aims to position itself as a global leader in enzyme innovation - accelerating the shift toward a cleaner, greener industrial economy. For the most current information and updates, please visit our website at www.quantumzymecorp.com. About Quantumzyme Corp. Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services—from discovery and engineering to process optimization and scale-up—Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard. Disclaimer The information contained in this press release is provided by Quantumzyme Corp. (“Quantumzyme”) for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management’s beliefs and assumptions as of the date of this press release and are subject to change without notice. Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates. Media Contact: Naveen Kulkarni View the original release on www.newmediawire.com News Source: Quantumzyme Corp
27.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Quantumzyme Corp |
United States | |
ISIN: | US75955E2054 |
EQS News ID: | 2107608 |
End of News | EQS News Service |
|
2107608 27.03.2025 CET/CEST
Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Quantumzyme
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Quantumzyme
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Quantumzyme Corp Registered Shs
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Quantumzyme Corp Registered Shs
Keine Analysen gefunden.